Arcellx/$ACLX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Ticker
$ACLX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
163
ISIN
US03940C1009
Website
Arcellx Metrics
BasicAdvanced
$3.7B
-
-$3.00
0.34
-
Price and volume
Market cap
$3.7B
Beta
0.34
52-week high
$107.37
52-week low
$47.86
Average daily volume
697K
Financial strength
Current ratio
4.928
Quick ratio
4.856
Long term debt to equity
10.993
Total debt to equity
12.759
Interest coverage (TTM)
-182.97%
Profitability
EBITDA (TTM)
-184.721
Gross margin (TTM)
-128.59%
Net profit margin (TTM)
-211.46%
Operating margin (TTM)
-248.22%
Effective tax rate (TTM)
-1.29%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-16.69%
Return on equity (TTM)
-35.56%
Valuation
Price to revenue (TTM)
46.805
Price to book
8.76
Price to tangible book (TTM)
8.76
Price to free cash flow (TTM)
-29.35
Free cash flow yield (TTM)
-3.41%
Free cash flow per share (TTM)
-226.03%
Growth
Revenue change (TTM)
-41.66%
Earnings per share change (TTM)
193.88%
3-year earnings per share growth (CAGR)
-40.68%
Bulls say / Bears say
Arcellx's lead product candidate, anitocabtagene autoleucel (anito-cel), demonstrated a 97% overall response rate and a 62% complete response rate in patients with relapsed or refractory multiple myeloma, indicating strong clinical efficacy. (stocktitan.net)
Analysts have set an average 12-month price target of $107.71 for Arcellx, suggesting significant upside potential from its current trading price. (nasdaq.com)
Billionaire investor Stanley Druckenmiller has included Arcellx among his top stock picks with substantial upside potential, reflecting confidence in the company's growth prospects. (finviz.com)
Arcellx reported a Q1 2025 loss of $1.13 per share, missing the consensus estimate of a $0.84 loss, indicating financial underperformance. (nasdaq.com)
The company's Q1 2025 revenues were $8.13 million, falling short of the consensus estimate by 55.30%, raising concerns about revenue generation. (nasdaq.com)
Insider selling activity, including the sale of 10,155 shares by insider Christopher Heery, may signal a lack of confidence in the company's near-term prospects. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Arcellx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcellx stock?
Arcellx (ACLX) has a market cap of $3.7B as of July 04, 2025.
What is the P/E ratio for Arcellx stock?
The price to earnings (P/E) ratio for Arcellx (ACLX) stock is 0 as of July 04, 2025.
Does Arcellx stock pay dividends?
No, Arcellx (ACLX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Arcellx dividend payment date?
Arcellx (ACLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcellx?
Arcellx (ACLX) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.